NCT06676033 is a Phase 1 clinical trial of epcoritamab in Leukemia, Chronic Lymphocytic, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Who is sponsoring NCT06676033?

NCT06676033 is sponsored by National Heart, Lung, and Blood Institute (NHLBI).

What drugs are being tested in NCT06676033?

Interventions in NCT06676033: epcoritamab.

What condition does NCT06676033 study?

NCT06676033 studies Leukemia, Chronic Lymphocytic, Richter Syndrome.

Is NCT06676033 still recruiting?

NCT06676033 is currently active, enrolled. Last updated 17 February 2026.

Last reviewed 2026-02-17 · How we verify

NCT06676033

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome

Active, enrolled Phase 1 Last updated 17 February 2026

What this trial tests

Phase 1 trial testing epcoritamab in Leukemia, Chronic Lymphocytic in 5 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 July 2025

Primary endpoint
1 July 2027

1 July 2027

Quick facts

Lead sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	5
Start date	18 July 2025
Primary completion	1 July 2027
Estimated completion	1 July 2027
Sites	1 location across United States

Drugs / interventions tested

epcoritamab (EPCORITAMAB) — full drug profile →

Conditions studied

Leukemia, Chronic Lymphocytic — all drugs for Leukemia, Chronic Lymphocytic →
Richter Syndrome — all drugs for Richter Syndrome →

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Who can join

Adults 18 to 100, any sex, with Leukemia, Chronic Lymphocytic or Richter Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This correlative study aims to understand the pharmacodynamic effects and clonal dynamics in response to epcoritamab by obtaining and analyzing lymph node, bone marrow, and blood samples from subjects enrolled in GCT3013-03 trial sponsored by Genmab at NIH. Samples will be collected before and at multiple time points during treatment with epcoritamab. National Heart, Lung, and Blood Institute (NHLBI) investigators are experienced in testing samples treated with bsAb2,3 including epcoritamab in an ongoing pre-clinical collaboration with Genmab. Addressing the objectives of this correlative study will advance the science and clinical application of epcoritamab specifically as well as T-cell engaging bsAb in general as an emerging class of immunotherapy for cancer. The study is enrolling by invitation only.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advancing Immunotherapy in Chronic Lymphocytic Leukemia.
Bieliński K, Wysocka A, Tyrna D, Robak T, et al · · 2026 · PMID 42123307 · DOI 10.3390/ijms27093722
Molecular Pathogenesis and Targeted Treatment of Richter Transformation
Maher N, Karami A, Matti B, Alwan A, et al · · 2026

Verify or expand the search:

Other recruiting trials for Leukemia, Chronic Lymphocytic

Currently open trials in the same condition.

NCT05947851 — A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) · Phase 3 · recruiting

Other National Heart, Lung, and Blood Institute (NHLBI) trials

Trials by the same sponsor.

NCT07566494 — Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06676033 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
Last refreshed: 17 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06676033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing